Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

Published: 9 July 2021| Version 2 | DOI: 10.17632/vr8fcbczz5.2
Lindsay Redman


p53 is mutated in over half of human cancers. In addition to losing wild-type (WT) tumor-suppressive function, mutant p53 proteins are proposed to acquire gain-of-function (GOF) activity, leading to novel oncogenic phenotypes. To study mutant p53 GOF mechanisms and phenotypes, we genetically engineered non-transformed and tumor-derived WT p53 cell line models to express endogenous missense mutant p53 (R175H and R273H) or to be deficient for p53 protein (null). Characterization of the models, which initially differed only by TP53 genotype, revealed that aneuploidy frequently occurred in mutant p53-expressing cells. GOF phenotypes occurred clonally in vitro and in vivo were independent of p53 alteration and correlated with increased aneuploidy. Further, analysis of outcome data revealed that individuals with aneuploid-high tumors displayed unfavorable prognoses, regardless of the TP53 genotype. Our results indicate that genetic variation resulting from aneuploidy accounts for the diversity of previously reported mutant p53 GOF phenotypes. The data herein represents the raw data and/or processed data from MCF10A and CAL-51 isogenic clonally-derived cell lines used in this manuscript, including RNA-sequencing, Whole Exome Sequencing, Cytogenomic Microarray Analysis, and analysis of gain-of-function phenotypes. Raw sequencing data that support the findings of this study have been deposited to the Sequence Read Archive under the BioProject accession number PRJNA669391.